Rocket Pharmaceuticals Inc

RCKTNASDAQ · USD
2.44USD+0.01 (-6.71%)
135

Rocket Pharmaceuticals Inc (RCKT) Covered Calls

Rocket Pharmaceuticals Inc trades in the Biotechnology industry with an IV Rank of 95.24%, high versus the past year. RCKT's highest covered call setup is the $5.00 strike expiring Jan 15, 2027, sorted by theoretical annualized return. It's 99.20% out of the money with 73 days to expiration, a 101.20% return until expiration, and a 505.98% theoretical annualized return. Across the setups shown, annualized returns run from 234.09% to 505.98% at strikes between $5.00 and $5.00, with 73 to 164 days to expiration, as of Nov 3, 2026.

Read more

Running RCKT covered calls helps you generate income from Rocket Pharmaceuticals Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best RCKT covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If RCKT stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling RCKT covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given RCKT covered call is worth writing.

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.

2027-01-15735.0099.200.050.15254.00101.20505.98-1.99+0.172,0880.10
2027-04-161645.0099.200.150.25264.00105.18234.09-5.98+0.266590.10

As of Nov 3, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank95.24% High
  • Market cap (M$)267
  • 52 weeks high-55.23%
  • 52 weeks low12.96%
  • Analyst recommendationBuy
    2.14
  • Target price$8.58
    251.64% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-05
  • P/E—
  • Future P/E—
  • EPS (ttm)-0.18
  • EPS growth next 5 years18.58%

As of Nov 5, 2026